Successful treatment of pleural and peritoneal larval mesocestoidosis with fenbendazole in two dogs.

Abstract

Mesocestoides spp. are common intestinal tapeworms of dogs and cats. The presence of numerous larval stages in the pleural or peritoneal cavities causes larval mesocestoidosis, that is a potentially life-threatening disease in massive infection. In vivo diagnosis of larval mesocestoidosis is challenging and confirmed diagnosis is often made post-mortem. For this reason, therapeutic recommendations are empirical and there is currently no data on the best treatment options in dogs and cats. Both fenbendazole and praziquantel have been used to treat canine larval mesocestoidosis but failure of complete clearance of larvae has been described for both. Treatment with fenbendazole at 100 mg/kg orally twice a day, for 1-3 months has been reported as being effective. However, it is known that administration of high, off-label doses of fenbendazole can lead to adverse reactions. Here, we report the efficacy of fenbendazole at a lower dosage (50 mg/kg twice a day) in two dogs with pleural and peritoneal mesocestoidosis.